drugset / Trial / NCT05751421

Pain Relief After PrimaryTKA

NCT05751421

Phase 3 Unknown 60 enrolled Rothman Institute Orthopaedics
RandomizedParallel-groupSingle-blindTreatment

Summary

While a majority of people who undergo TKA have significant long-term improvement in functional ability, many patients may experience significant pain in the early postoperative period, which may adversely impact postoperative rehabilitation and recovery. Traditionally, opioid medications have been used to control postoperative pain. However, there are many risks with using opioid medications, including addiction and overdose, which kills over 48,000 people yearly. In an effort to overcome this, opioid-sparing multimodal analgesia (MMA) regimens have been developed, commonly using nonsteroid anti-inflammatory drugs (NSAIDs), acetaminophen, regional nerve blocks, and local anesthesia.

Timeline

Start
2023-02-28
Primary completion
2024-02-28
Completion
2024-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine Other / unclassified 0.5 %
Subject Bupivacaine Other / unclassified 60 mg
Subject Meloxicam Small molecule 1.8 mg

Indications